We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can Solid EPD Business Drive Abbott's (ABT) Q1 Earnings?
Read MoreHide Full Article
Abbott’s (ABT - Free Report) Established Pharmaceuticals Division (“EPD”) business has been recording operational sales growth in the last few quarters. We expect this strength to get reflected in first-quarter 2018 results as well, which are scheduled for release on Apr 18.
Click here to know how the company’s overall Q1 performance is expected to be.
Key Catalysts
This business majorly focuses on emerging markets. Notably, the key emerging markets include India, Russia, China and numerous others in Latin America as well as Brazil along with other countries. Sales in key emerging markets increased 15% (up 12.5%on comparable operational basis) driven by double-digit growth in India, China and Latin America in the last reported quarter.
Moreover, management believes that these emerging markets will continue to offer immense opportunities with favorable demographics. Accordingly, the Zacks Consensus Estimate for EPD revenues from key emerging markets of $844 million indicates a rise of 15.6% from the year-ago quarter.
Although immaterial for the to-be-reported quarter, the ongoing tensions between the United States and China regarding the imposition of tariffs on imports, has raised concerns for major MedTech players as any adverse move may affect their sales performance in China in near term.
We encouragingly note that, management expects high single-digit growth in EPD sales in the first quarter of 2018. Furthermore, the Zacks Consensus Estimate for EPD revenues of $1.09 billion shows a rise of 14.7% from the year-ago quarter.
Favorable currency translation also had a positive impact of 1.4% on EPD revenues in the last reported quarter. We encouragingly note that, management expects foreign exchange to continue to act as a tailwind in the to-be-reported quarter.
In EPD, Abbott’s consistent focus on enhancing local capabilities and expanding product portfolio within core therapeutic areas is targeted specifically to address local market needs. These efforts from the company also continue to strengthen its leadership position in the EPD markets. Abbott’s sale of developed market businesses along with acquisitions of CFR Pharmaceuticals in Latin America and Veropharm in Russia has contributed to the EPD business.
Zacks Rank & Stocks to Consider
Abbott carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical sector are Bio-Rad Laboratories (BIO - Free Report) , Myriad Genetics, Inc. (MYGN - Free Report) and Abiomed, Inc .
Myriad Genetics has long-term expected earnings growth rate of 10%. The stock carries a Zacks Rank of 2 (Buy).
Abiomed has long-term expected earnings growth rate of 31.5%. The stock carries a Zacks Rank of 2.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Can Solid EPD Business Drive Abbott's (ABT) Q1 Earnings?
Abbott’s (ABT - Free Report) Established Pharmaceuticals Division (“EPD”) business has been recording operational sales growth in the last few quarters. We expect this strength to get reflected in first-quarter 2018 results as well, which are scheduled for release on Apr 18.
Click here to know how the company’s overall Q1 performance is expected to be.
Key Catalysts
This business majorly focuses on emerging markets. Notably, the key emerging markets include India, Russia, China and numerous others in Latin America as well as Brazil along with other countries. Sales in key emerging markets increased 15% (up 12.5%on comparable operational basis) driven by double-digit growth in India, China and Latin America in the last reported quarter.
Moreover, management believes that these emerging markets will continue to offer immense opportunities with favorable demographics. Accordingly, the Zacks Consensus Estimate for EPD revenues from key emerging markets of $844 million indicates a rise of 15.6% from the year-ago quarter.
Although immaterial for the to-be-reported quarter, the ongoing tensions between the United States and China regarding the imposition of tariffs on imports, has raised concerns for major MedTech players as any adverse move may affect their sales performance in China in near term.
Abbott Laboratories Price and EPS Surprise
Abbott Laboratories Price and EPS Surprise | Abbott Laboratories Quote
We encouragingly note that, management expects high single-digit growth in EPD sales in the first quarter of 2018. Furthermore, the Zacks Consensus Estimate for EPD revenues of $1.09 billion shows a rise of 14.7% from the year-ago quarter.
Favorable currency translation also had a positive impact of 1.4% on EPD revenues in the last reported quarter. We encouragingly note that, management expects foreign exchange to continue to act as a tailwind in the to-be-reported quarter.
In EPD, Abbott’s consistent focus on enhancing local capabilities and expanding product portfolio within core therapeutic areas is targeted specifically to address local market needs. These efforts from the company also continue to strengthen its leadership position in the EPD markets. Abbott’s sale of developed market businesses along with acquisitions of CFR Pharmaceuticals in Latin America and Veropharm in Russia has contributed to the EPD business.
Zacks Rank & Stocks to Consider
Abbott carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical sector are Bio-Rad Laboratories (BIO - Free Report) , Myriad Genetics, Inc. (MYGN - Free Report) and Abiomed, Inc .
Bio-Rad Laboratories sports a Zacks Rank of 1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. It has long-term expected earnings growth rate of 15%.
Myriad Genetics has long-term expected earnings growth rate of 10%. The stock carries a Zacks Rank of 2 (Buy).
Abiomed has long-term expected earnings growth rate of 31.5%. The stock carries a Zacks Rank of 2.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>